Vaccinex

Vaccinex Forward P/E

The Forward P/E Ratio of Vaccinex (VCNX) as of Nov 20, 2026 is -0.76. In the previous year, Forward P/E Ratio was -0.21 — a change of 254.26% (lower).

Forward P/E

-0.76

YoY

254.26%

Last updated:

Forward P/E Ratio of Vaccinex is 2025 -0.76 . Forward P/E Ratio of Vaccinex was 2024 -0.21 . It decreases by 254.26% lower compared to the previous year.

The Vaccinex Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-0.14 USD
Jan 1, 2019
-0.12 USD
Jan 1, 2020
-0.14 USD
Jan 1, 2021
-0.18 USD
Jan 1, 2022
-0.20 USD
Jan 1, 2023
-0.20 USD
Jan 1, 2024
-0.21 USD
Jan 1, 2025
-0.76 USD
The Vaccinex Forward P/E history
YEARForward P/EYoY
-0.76+254.26%
-0.21+8.68%
-0.20-2.61%
-0.20+13.48%
-0.18+28.91%
-0.14+10.97%
-0.12-7.80%
-0.14-36.57%
-0.21-25.53%
-0.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaccinex Stock analysis

What does Vaccinex do? Vaccinex, Inc. develops targeted biotherapeutics for serious diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The company generates revenue through its SEMA4D antibody platform, focusing on VX15 for non-small cell lung cancer, osteosarcoma, melanoma, and Huntington’s disease. It also utilizes the ActiveMAb antibody discovery platform for developing VX5, which is in preclinical stages for multiple sclerosis and other autoimmune disorders. Vaccinex targets healthcare providers and pharmaceutical companies seeking novel treatments for unmet medical needs. Vaccinex's lead product candidate VX15 is developed using the SEMA4D platform to address non-small cell lung cancer, osteosarcoma, and melanoma. The company's ActiveMAb platform supports the creation of high-affinity human monoclonal antibodies, which are used in VX5 for multiple sclerosis treatment. These platforms enable Vaccinex to offer innovative solutions for diseases with limited therapeutic options. The company's focus on clinical-stage development means it currently does not generate revenue from product sales but relies on partnerships and potential future licensing agreements. Vaccinex's target segments include patients with non-small cell lung cancer, osteosarcoma, melanoma, Huntington’s disease, and multiple sclerosis, as well as pharmaceutical companies interested in acquiring or co-developing its platforms and product candidates. Vaccinex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaccinex stock

Forward P/E Ratio of Vaccinex is -0.76 in 2025.

Forward P/E Ratio of Vaccinex changed from -0.21 to -0.76, representing a 254.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Vaccinex since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Vaccinex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vaccinex

All Key Metrics — Vaccinex